Mediastinal lymph node examination and survival in resected early-stage non-small-cell lung cancer in the surveillance, epidemiology, and end results database

Journal of Thoracic Oncology

Volumn 7, Issue 12, 2012, Pages 1798-1806

  Osarogiagbon, Raymond U ^a   Yu, Xinhua ^b  

^a Boston Baskin Cancer Foundation   (United States)

^b UNIVERSITY OF MEMPHIS   (United States)

Author keywords

Mediastinal lymph nodes; Non small cell lung cancer; Outcome of care; Quality of care; Staging; Surgical resection

Indexed keywords

ADULT; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; MEDIASTINUM LYMPH NODE METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME;

EID: 84870380626     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31827457db     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3. Goldstraw P, Crowley J, Chansky K, et al. International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714. (Pubitemid 47357522)
4. Rusch VW, Crowley J, Giroux DJ, et al. International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:603-612. (Pubitemid 47171781)
5. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
6. Winton T, Livingston R, Johnson D, et al. National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597. (Pubitemid 41007845)
7. Pignon JP, Tribodet H, Scagliotti GV, et al.; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-3559.
8. Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006;24:2998-3006. (Pubitemid 46638932)
9. Fernando HC, Goldstraw P. The accuracy of clinical evaluative intrathoracic staging in lung cancer as assessed by postsurgical pathologic staging. Cancer 1990;65:2503-2506. (Pubitemid 20168938)
10. D'Cunha J, Herndon JE, II Herzan DL, et al.; Cancer and Leukemia Group B. Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial. Lung Cancer 2005;48:241-246.
11. Annema JT, van Meerbeeck JP, Rintoul RC, et al. Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA 2010;304:2245-2252.
12. Association of Directors of Anatomic and Surgical Pathology. Recommendations for processing and reporting of lymph node specimens submitted for evaluation of metastatic disease. Am J Clin Pathol 2001;115:799-801.
13. Rami-Porta R, Wittekind C, Goldstraw P. International Association for the Study of Lung Cancer (IASLC) Staging Committee. Complete resection in lung cancer surgery: proposed definition. Lung Cancer 2005;49:25-33.
14. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
15. Lardinois D, De Leyn P, Van Schil P, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg 2006;30:787-792. (Pubitemid 44572768)
16. Part IV, Thorax. In Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds.), AJCC Cancer Staging Handbook, 7th Ed. New York, NY: Springer; 2010: 297-323.
17. Available at: http://www.nccn.org/professionals/physician-gls/pdf/nscl. pdf. Accessed December 16, 2011.
18. Izbicki JR, Passlick B, Pantel K, et al. Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial. Ann Surg 1998;227:138-144. (Pubitemid 28071349)
19. Wu Y, Huang ZF, Wang SY, Yang XN, Ou W. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer 2002;36:1-6. (Pubitemid 34224887)
20. Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 2011;141:662-670.
21. Graham ANJ, Chan KJM, Pastorino U, Goldstraw P. Systematic nodal dissection in the intrathoracic staging of patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 1999;11:246-251. (Pubitemid 29068380)
22. Veeramachaneni NK, Battafarano RJ, Meyers BF, Zoole JB, Patterson GA. Risk factors for occult nodal metastasis in clinical T1N0 lung cancer: a negative impact on survival. Eur J Cardiothorac Surg 2008;33:466-469.
23. Fukui T, Mori S, Yokoi K, Mitsudomi T. Significance of the number of positive lymph nodes in resected non-small cell lung cancer. J Thorac Oncol 2006;1:120-125. (Pubitemid 47163998)
24. Lee JG, Lee CY, Park IK, et al. Number of metastatic lymph nodes in resected non-small cell lung cancer predicts patient survival. Ann Thorac Surg 2008;85:211-215. (Pubitemid 350265823)
25. Little AG, Rusch VW, Bonner JA, et al. Patterns of surgical care of lung cancer patients. Ann Thorac Surg 2005;80:2051-2056. (Pubitemid 41718027)
26. Varlotto JM, Recht A, Nikolov M, Flickinger JC, Decamp MM. Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer. Cancer 2009;115:851-858.
27. Allen JW, Farooq A, O'Brien TF, Osarogiagbon RU. Quality of surgical resection for nonsmall cell lung cancer in a US metropolitan area. Cancer 2011;117:134-142.
28. Osarogiagbon RU, Allen JW, Farooq A, Berry A, Spencer D, O'Brien T. Outcome of surgical resection for pathologic N0 and Nx non-small cell lung cancer. J Thorac Oncol 2010;5:191-196.
29. Osarogiagbon RU, Allen JW, Farooq A, Berry A, O'Brien T. Pathologic lymph node staging practice and stage-predicted survival after resection of lung cancer. Ann Thorac Surg 2011;91:1486-1492.
30. Osarogiagbon RU, Allen JW, Farooq A, Wu JT. Objective review of mediastinal lymph node examination in a lung cancer resection cohort. J Thorac Oncol 2012;7:390-396.
31. Silvestri GA, Handy J, Lackland D, Corley E, Reed CE. Specialists achieve better outcomes than generalists for lung cancer surgery. Chest 1998;114:675-680. (Pubitemid 28433723)
32. Schipper PH, Diggs BS, Ungerleider RM, Welke KF. The influence of surgeon specialty on outcomes in general thoracic surgery: a national sample 1996 to 2005. Ann Thorac Surg 2009;88:1566-1572.
33. Farjah F, Flum DR, Varghese TK Jr, Symons RG, Wood DE. Surgeon specialty and long-term survival after pulmonary resection for lung cancer. Ann Thorac Surg 2009;87:995-1004; discussion 1005.
34. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med 2003;349:2117-2127. (Pubitemid 37464537)
35. Bach PB, Cramer LD, Schrag D, Downey RJ, Gelfand SE, Begg CB. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 2001;345:181-188. (Pubitemid 32662128)
36. Bilimoria KY, Bentrem DJ, Feinglass JM, et al. Directing surgical quality improvement initiatives: comparison of perioperative mortality and long-term survival for cancer surgery. J Clin Oncol 2008;26:4626-4633.
37. Meguid RA, Brooke BS, Chang DC, Sherwood JT, Brock MV, Yang SC. Are surgical outcomes for lung cancer resections improved at teaching hospitals? Ann Thorac Surg 2008;85:1015-1024.
38. Gephardt GN, Baker PB. Lung carcinoma surgical pathology report adequacy: a College of American Pathologists Q-Probes study of over 8300 cases from 464 institutions. Arch Pathol Lab Med 1996;120:922-927. (Pubitemid 26346455)
39. Ramirez RA, Wang CG, Miller LE, et al. Incomplete intrapulmonary lymph node retrieval after routine pathologic examination of resected lung cancer. J Clin Oncol 2012;30:2823-2828.
40. Osarogiagbon RU, Miller LE, Ramirez RA, et al. Use of a surgical specimen-collection kit to improve mediastinal lymph-node examination of resectable lung cancer. J Thorac Oncol 2012;7:1276-1282.
41. Detterbeck F, Puchalski J, Rubinowitz A, Cheng D. Classification of the thoroughness of mediastinal staging of lung cancer. Chest 2010;137:436-442.
42. Gajra A, Newman N, Gamble GP, Kohman LJ, Graziano SL. Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer. J Clin Oncol 2003;21:1029-1034. (Pubitemid 46594131)
43. Detterbeck FC. The fable of Babel and building a foundation for quality. J Thorac Oncol 2012;7:267-268.